top of page
About Us
CEO Message
History
Contact Us
R&D
Core Technology
Publications
Pipeline
IMB001
IMB002
IR/PR
Notice
Press Release
Career
Recruitment Information
Talents
Employee Benefits
< Back
이뮤노바이옴, 아토피 피부염 신약 후보물질 1/2a상 임상시험계획 FDA 승인
메디컬투데이
Previous
Next
bottom of page